Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies

Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies

Bevacizumab targets the vascular endothelial growth factor signaling pathway, inhibiting tumor angiogenesis and reshaping the tumor microenvironment, positioning it as a cornerstone in ovarian cancer management. Its mechanisms of action include blocking VEGF-A-induced endothelial cell proliferation,...

Full description

Saved in:
Bibliographic Details
Main Authors: Mingyue Zhang, Jun Zhu, Yin Bao, Qiang Ao, Xiaoling Mao, Zhengzhou Qiu, Yiming Zhang, Yang Chen, Hong Zhu, Jun Gao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Bioengineering and Biotechnology
Subjects:
bevacizumab
ovarian cancer
tumor angiogenesis
drug resistance
nanodrug delivery
Online Access:https://www.frontiersin.org/articles/10.3389/fbioe.2025.1589841/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fbioe.2025.1589841/full

Similar Items